CheckmAb is a biotech start-up focused on developing novel monoclonal antibodies for cancer immunotherapy. The company aims to identify subtypes of immune system cells involved in the immunological response for tumors, with the goal of determining biomarkers for the development of more selective immunoglobulin therapies. CheckmAb's antibodies target tumor-infiltrating regulatory T lymphocytes, unleashing the immunological response only within the neoplastic lesion to avoid harmful systemic autoimmune reactions associated with current immunotherapies. The company's ultimate goal is to provide safer and more effective cancer therapies for patients.